QALSODY targets the root cause of SOD1-ALS, an ultra-rare and uniformly fatal neurodegenerative disease marked by motor neuron loss in the brain and spinal cord 1 Biogen's second rare disease therapy ...
QALSODY is the first therapy designed to address the underlying genetic cause of SOD1-ALS2, a rapidly progressive and uniformly fatal condition that impacts motor function, speech, and respiratory ...
スーパーオキシドジスムターゼ1（SOD1）遺伝子変異がある筋萎縮性側索硬化症（SOD1ALS）患者を対象に、アンチセンスオリゴヌクレオチドtofersen髄腔内投与の有効性を第III相試験で検討（VALOR試験）。主要評価項目は、急速な進行が予測された患者のALS機能評価 ...
HTA assessments highlight importance of timely and equitable access to QALSODY for this ultra-rare genetic form of ALS and urgent need for therapies that slow progression, preserve function and ...
The MarketWatch News Department was not involved in the creation of this content. -- CDA issues positive reimbursement recommendation for QALSODY -- INESSS recognizes QALSODY's promising clinical ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Neurofilament light chain and cerebrospinal fluid ...
Early initiation of tofersen (Qalsody) was associated with a numerically slower decline in people with SOD1 amyotrophic lateral sclerosis (ALS) compared with delayed treatment, according to data from ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する